Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
  • A61K38/07—Tetrapeptides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
  • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
  • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
  • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
  • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
  • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
  • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
  • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
  • C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
  • C07F5/02—Boron compounds
  • C07F5/025—Boronic and borinic acid compounds
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/06—Dipeptides
  • C07K5/06008—Dipeptides with the first amino acid being neutral
  • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
  • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
  • C07K5/06052—Val-amino acid
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
  • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
  • C07K5/10—Tetrapeptides
  • C07K5/1002—Tetrapeptides with the first amino acid being neutral
  • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
  • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
  • C07K7/04—Linear peptides containing only normal peptide links
  • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

• an antibody or antibody fragment such as a single-chain variable fragment
• ADC antibody-drug conjugate
• Some embodiments provide active agent-conjugates, methods of preparing active agent-conjugates, and uses thereof.
• Some embodiments provide an active agent-conjugate having the structure of Formula I:
• A may be a targeting moiety
• B may be an auxiliary moiety that optionally is a second targeting moiety, or B may be null;
• L 1 includes a 2- to 5 -carbon bridge and at least one sulfur atom
• each D may be independently selected, where each D includes an active agent
• each L 2 may be independently a linker, wherein at least one L 2 links to L 1 ;
• n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• Some embodiments provide an active agent-conjugate having the structure of Formula la:
• the A-component may be a targeting moiety
• the E-component may be an optionally substituted heteroaryl or an optionally substituted heterocyclyl
• B may be an auxiliary moiety that optionally is a second targeting moiety, or B may be null;
• each D may be independently selected, where each D includes an active agent
• each L 2 may be independently a linker, wherein at least one L 2 links to L 1 ;
• n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
• L 3 may be an optionally substituted Ci-C 6 alkyl, or L 3 may be null, when L 3 is null the sulfur is directly connected to the E-component;
• L 4 may be an optionally substituted Ci-C 6 alkyl, or L 4 may be null, when L 4 is null the sulfur is directly connected to the E-component.
• the E-component includes a fragment selected from the group consisting of:
• L 3 may be -(CH 2 )-; and L 4 may be -(CH 2 )-. In some embodiments L 3 may be null; and L 4 may be null.
• L 2 includes -(CH 2 ) n - where n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, L 2 includes -(CH 2 CH 2 0) n - where n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, L 2 includes Val-Cit-PAB, Val-Ala- PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly- Arg, Ala-Ala-Asn-PAB, Ala-PAB, or PAB.
• L 2 includes peptide, oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)- PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn- PAB, Ala-PAB, PAB, or combinations thereof.
• L 2 includes a noncleavable unit.
• the noncleavable unit includes -(CH 2 ) compassion- where n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, the noncleavable unit includes -(CH 2 CH 2 0) n - where n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, L 2 includes a cleavable unit. In some embodiments, the cleavable unit comprises a peptide.
• the A component comprises a monoclonal antibody (mAB). In some embodiments, the A component comprises an antibody fragment, surrogate, or variant. In some embodiments, the A component comprises a protein ligand. In some embodiments, the A component comprises a protein scaffold. In some embodiments, the A component comprises a peptide. In some embodiments, the A component comprises a small molecule ligand. In some embodiments, the A component comprises at least one modified L-Alanine residue. In some embodiments, the A component comprises at least two modified L- Alanine residues. In some embodiments, at least one L 2 includes -(CH 2 ) n - where n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• At least one L 2 includes -(CH 2 CH 2 0) n - where n may be 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• at least one L 2 includes Val-Cit-PAB, Val- Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala- Ala- Asn-PAB, Ala-PAB, or PAB.
• At least one L 2 includes a peptide, an oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala- Ala-Asn-PAB, Ala-PAB, PAB or combinations thereof.
• Figure 1 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 5.5 : 1.
• Figure 2 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 6: 1.
• Figure 3 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 1 :6.5.
• Figure 4 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 1 :4
• Figure 5 shows HIC-HPLC chromatograms for each FPLC fraction, and, inset, an overlay of the peaks to demonstrate relative purity of each peak.
• Figure 6 shows reduced SDS-PAGE analysis for the FPLC fractions depicted in Figures 4 and 5.
• Figure 7 shows viability of SK-BR-3 cells for seven antibody-drug conjugate samples.
• Figure 8 shows viability of HCC1954 cells for seven antibody-drug conjugate samples.
• Figure 9 shows reduced SDS-PAGE analysis for trastuzumab conjugated compound 40.
• Figure 10 shows viability of SK-BR-3 cells for four antibody-drug conjugate samples.
• Figure 11 shows viability of HCC1954 cells for four antibody-drug conjugate samples.
• Figure 12 shows viability of SK-BR-3 cells for four antibody-drug conjugate samples.
• the active agent-conjugate is a drug-conjugate.
• the drug-conjugate includes a targeting molecule.
• the targeting molecule includes a monoclonal antibody (mAB).
• the drug- conjugate includes a spacer or a multifunctional linker.
• the spacer connects to the mAB by a sulfide bond.
• the multifunctional linker connects to the mAB by a sulfide bond.
• the spacer or multifunctional linker may be optionally connected to an auxiliary moiety.
• the auxiliary moiety may be a second targeting molecule such as mAB and peptide.
• the auxiliary moiety may be a hydrophilic polymer such as polyethylene glycol (PEG), and the like.
• the spacer or multifunctional linker may include a 2- to 5- atom bridge. In some embodiments, the spacer or multifunctional linker may include a 4C (four carbon) bridge.
• Conjugation methods to derivatize a polypeptide with a payload can be accomplished using a maleimido or vinyl moiety which can react with individual sulfhydryl group on an antibody via Michael addition reaction.
• the free sulfhydryl group can be formed by reducing a disulfide bond in an antibody.
• the structural integrity of an antibody can be compromised after opening disulfide bonds and attaching payloads to the exposed free thiols.
• the compositions and methods provided herein provide conjugation through cysteine without decreased structural stability.
• pharmaceutically acceptable salt refers to salts that retain the biological effectiveness and properties of a compound and, which are not biologically or otherwise undesirable for use in a pharmaceutical.
• the compounds disclosed herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
• Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
• Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
• Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
• Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
• Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87/05297, Johnston et al, published September 11, 1987 (incorporated by reference herein in its entirety).
• C a to C b or "C a -b” in which "a” and “b” are integers refer to the number of carbon atoms in the specified group. That is, the group can contain from “a” to "b", inclusive, carbon atoms.
• a “Ci to C 4 alkyl” or “Ci_ 4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 -, CH 3 CH 2 - , CH 3 CH 2 CH 2 -, (CH 3 ) 2 CH-, CH 3 CH 2 CH 2 CH 2 -, CH 3 CH 2 CH(CH 3 )- and (CH 3 ) 3 C-.
• halogen or “halo,” as used herein, means any one of the radio-stable atoms of column 7 of the Periodic Table of the Elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
• alkyl refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds).
• the alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., "1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated).
• the alkyl group may also be a medium size alkyl having 1 to 9 carbon atoms.
• the alkyl group could also be a lower alkyl having 1 to 4 carbon atoms.
• the alkyl group may be designated as "Ci_ 4 alkyl" or similar designations.
• Ci_ 4 alkyl indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
• Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
• alkoxy refers to the formula -OR wherein R is an alkyl as is defined above, such as “Ci_9 alkoxy”, including but not limited to methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy, and the like.
• alkylthio refers to the formula -SR wherein R is an alkyl as is defined above, such as "Ci_g alkylthio” and the like, including but not limited to methylmercapto, ethylmercapto, n-propylmercapto, 1-methylethylmercapto (isopropylmercapto), n-butylmercapto, iso-butylmercapto, sec-butylmercapto, tert- butylmercapto, and the like.
• alkenyl refers to a straight or branched hydrocarbon chain containing one or more double bonds.
• the alkenyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl” where no numerical range is designated.
• the alkenyl group may also be a medium size alkenyl having 2 to 9 carbon atoms.
• the alkenyl group could also be a lower alkenyl having 2 to 4 carbon atoms.
• the alkenyl group may be designated as "C 2 _ 4 alkenyl" or similar designations.
• C 2 _ 4 alkenyl indicates that there are two to four carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-l-yl, propen-2-yl, propen-3-yl, buten-l-yl, buten-2- yl, buten-3-yl, buten-4-yl, 1-methyl-propen-l-yl, 2-methyl-propen-l-yl, 1-ethyl-ethen-l- yl, 2-methyl-propen-3-yl, buta-l,3-dienyl, buta-l,2,-dienyl, and buta-l,2-dien-4-yl.
• Typical alkenyl groups include, but are in no way limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl, and the like.
• alkynyl refers to a straight or branched hydrocarbon chain containing one or more triple bonds.
• the alkynyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl” where no numerical range is designated.
• the alkynyl group may also be a medium size alkynyl having 2 to 9 carbon atoms.
• the alkynyl group could also be a lower alkynyl having 2 to 4 carbon atoms.
• the alkynyl group may be designated as "C 2 _ 4 alkynyl" or similar designations.
• C 2 _ 4 alkynyl indicates that there are two to four carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-l-yl, propyn-2-yl, butyn-l-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl.
• Typical alkynyl groups include, but are in no way limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl, and the like.
• aromatic refers to a ring or ring system having a conjugated pi electron system and includes both carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine).
• carbocyclic aromatic e.g., phenyl
• heterocyclic aromatic groups e.g., pyridine
• the term includes monocyclic or fused- ring polycyclic (i.e., rings which share adjacent pairs of atoms) groups provided that the entire ring system is aromatic.
• aryloxy and arylthio refers to RO- and RS-, in which R is an aryl as is defined above, such as “C 6 -io aryloxy” or “C 6 -io arylthio” and the like, including but not limited to phenyloxy.
• an "aralkyl” or “arylalkyl” is an aryl group connected, as a substituent, via an alkylene group, such as "C 7-14 aralkyl” and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl.
• the alkylene group is a lower alkylene group (i.e., a C 1-4 alkylene group).
• heteroaryl refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent atoms) that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the ring backbone.
• heteroaryl is a ring system, every ring in the system is aromatic.
• the heteroaryl group may have 5-18 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heteroaryl" where no numerical range is designated.
• the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members.
• the heteroaryl group may be designated as "5-7 membered heteroaryl,” "5-10 membered heteroaryl,” or similar designations.
• heteroaryl rings include, but are not limited to, furyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinlinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothienyl.
• a “heteroaralkyl” or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group. Examples include but are not limited to 2- thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazollylalkyl, and imidazolylalkyl.
• the alkylene group is a lower alkylene group (i.e., a Ci_ 4 alkylene group).
• carbocyclyl means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone.
• carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged or spiro- connected fashion.
• Carbocyclyls may have any degree of saturation provided that at least one ring in a ring system is not aromatic.
• carbocyclyls include cycloalkyls, cycloalkenyls, and cycloalkynyls.
• the carbocyclyl group may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term "carbocyclyl” where no numerical range is designated.
• the carbocyclyl group may also be a medium size carbocyclyl having 3 to 10 carbon atoms.
• the carbocyclyl group could also be a carbocyclyl having 3 to 6 carbon atoms.
• the carbocyclyl group may be designated as "C3-6 carbocyclyl" or similar designations.
• carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3- dihydro-indene, bicycle[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
• a "(carbocyclyl)alkyl” is a carbocyclyl group connected, as a substituent, via an alkylene group, such as "C 4 _io (carbocyclyl)alkyl” and the like, including but not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like.
• the alkylene group is a lower alkylene group.
• cycloalkyl means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• cycloalkenyl means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. An example is cyclohexenyl.
• heterocyclyl means a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be joined together in a fused, bridged or spiro-connected fashion. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. The heteroatom(s) may be present in either a non-aromatic or aromatic ring in the ring system.
• the heterocyclyl group may have 3 to 20 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heterocyclyl” where no numerical range is designated.
• the heterocyclyl group may also be a medium size heterocyclyl having 3 to 10 ring members.
• the heterocyclyl group could also be a heterocyclyl having 3 to 6 ring members.
• the heterocyclyl group may be designated as "3-6 membered heterocyclyl" or similar designations.
• the heteroatom(s) are selected from one up to three of O (oxygen), N (nitrogen) or S (sulfur), and in preferred five membered monocyclic heterocyclyls, the heteroatom(s) are selected from one or two heteroatoms selected from O (oxygen), N (nitrogen), or S (sulfur).
• heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4-piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxanyl, 1 ,4-dioxinyl, 1 ,4-dioxanyl, 1,3-oxathianyl, 1,4- oxathiinyl, 1 ,4-oxathianyl, 2H-l,2-oxazinyl, triox
• a "(heterocyclyl)alkyl” is a heterocyclyl group connected, as a substituent, via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
• R is selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C3-7 carbocyclyl, C 6 -io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• a "cyano” group refers to a "-CN” group.
• a "cyanato” group refers to an "-OCN” group.
• An "isocyanato” group refers to a "-NCO” group.
• a "thiocyanato" group refers to a "-SCN” group.
• An “isothiocyanato” group refers to an “-NCS” group.
• a “sulfonyl” group refers to an "-S0 2 R” group in which R is selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C3-7 carbocyclyl, C 6 -io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• S-sulfonamido refers to a "-S0 2 NR A RB” group in which RA and RB are each independently selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C3-7 carbocyclyl, C 6 -io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• N-sulfonamido refers to a "-N(R A )S0 2 R B " group in which RA and Rb are each independently selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C3-7 carbocyclyl, C 6 -io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• An “amino” group refers to a "-NR A R B " group in which R A and R B are each independently selected from hydrogen, Ci_ 6 alkyl, C 2 - 6 alkenyl, C 2 - 6 alkynyl, C 3 - 7 carbocyclyl, C 6 _io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
• a non- limiting example includes free amino (i.e., -NI3 ⁇ 4).
• aminoalkyl refers to an amino group connected via an alkylene group.
• alkoxyalkyl refers to an alkoxy group connected via an alkylene group, such as a "C 2 _8 alkoxyalkyl” and the like.
• a substituted group is derived from the unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms for another atom or group.
• substituted it is meant that the group is substituted with one or more subsitutents independently selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C7 carbocyclyl (optionally substituted with halo, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkyl, and Ci-C 6 haloalkoxy), C 3 -Cy-carbocyclyl-Ci-C 6 -alkyl (optionally substituted with halo, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkyl, and Ci-C 6 haloalkoxy
• radical naming conventions can include either a mono-radical or a di-radical, depending on the context.
• a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
• a substituent identified as alkyl that requires two points of attachment includes di-radicals such as -CH 2 -, - CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, and the like.
• radical naming conventions clearly indicate that the radical is a di-radical such as "alkylene” or "alkenylene.”
• a substituent is depicted as a di-radical (i.e., has two points of attachment to the rest of the molecule), it is to be understood that the substituent can be attached in any directional configuration unless otherwise indicated.
• a substituent depicted as -AE- or v 3 ⁇ 4 A ⁇ E A includes the substituent being oriented such that the A is attached at the leftmost attachment point of the molecule as well as the case in which A is attached at the rightmost attachment point of the molecule.
• Subject as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
• Some embodiments provide a method of conjugating of a targeting molecule through a spacer or a multifunctional linker.
• the spacer or multifunctional linker may include a 2- to 5- atom bridge.
• the method includes a single-step or sequential conjugation approach.
• the drug-conjugates include a spacer or a multifunctional linker.
• the spacer or multifunctional linker may include a noncleavable or cleavable unit such as peptides.
• Some embodiments provide a method of treating a patient in need thereof comprising administering an active agent-conjugate as disclosed and described herein to said patient.
• the patient may have cancer, immune diseases or diabetes.
• Some embodiments provide a method of diagnosis or imaging comprising administering an active agent-conjugate as disclosed and described herein to an individual.
• Some embodiments provide an active agent-conjugate having the structure of Formula I
• A may be a targeting molecule
• B is an auxiliary moiety that optionally is a second targeting molecule, or B is null;
• L 1 includes a 2- to 5 -carbon bridge and at least one sulfur atom
• each D is independently selected, where each D includes an active agent
• each L 2 is independently a linker, wherein at least one L 2 links to L 1 ;
• n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• A may be a monoclonal antibody (mAB).
• A may be an antibody fragment, surrogate, or variant.
• A may be a protein ligand.
• A may be a protein scaffold.
• A may be a peptide
• A may be a small molecule ligand.
• B may be a hydrophilic polymer.
• the hydrophilic polymer may polyethylene glycol (PEG), and the like.
• B may be a biodegradable polymer.
• the biodegradable polymer may be unstructured proteins polyamino acids, polypeptides polysaccharides and combinations thereof.
• B may be a monoclonal antibody (mAB).
• B may be an antibody fragment, surrogate, or variant.
• B may be a protein ligand.
• B may be a protein scaffold.
• B may be a peptide.
• B may be R A or DNA.
• B may be a RNA or DNA fragment.
• B may be a small molecule ligand.
• D may be a biologically active compound.
• D may be a drug
• D may be a chemotherapy drug.
• D may be a natural product.
• D may be an immune modulator.
• D may be a tubulin-binder
• D may be a DNA-alkylating agent.
• D may be an HSP90 inhibitor.
• D may be a DNA topoisomerase inhibitor.
• D may be an anti-epigenetic agent.
• D may be an HDAC inhibitor.
• D may be an anti-metabolism agent.
• D may be a proteasome inhibitor.
• D may be a peptide
• D may be a peptidomimetic
• D may be an siRNA.
• D may be an antisense DNA.
• D may be epothilone A, epothilone B, or paclitaxel.
• L 2 may include a spacer or a multifunctional linker. In some embodiments, L 2 may include a spacer and a multifunctional linker. In some embodiments, L 2 may include a multifunctional linker. In some embodiments, each L 2 may be a linker, wherein the linker may be cleavable or non-cleavable under biological conditions. In some embodiments, the linker may be cleavable by an enzyme. In some embodiments, L 2 may include Linker.
• L 1 includes a 2- to 5-carbon bridge and at least one sulfur atom. In some embodiments, L 1 includes a 2- to 5-carbon bridge and at least two sulfur atoms. In some embodiments, L 1 includes a 2- to 5-carbon bridge and a spacer. In some embodiments, L 1 includes a 2- to 5-carbon bridge, at least two sulfur atoms and a spacer. In some embodiments, L 1 may include one or more sulfurs. In some embodiments, the L 1 may include two or more sulfurs. In some embodiments, the L 1 may include exactly two sulfurs. In some embodiments, may include a 4-carbon bridge and/or a spacer. In some embodiments, L 1 include a 4-carbon bridge or a spacer.
• L 1 may include a 4-carbon bridge and a spacer. In some embodiments, L 1 includes a 4-carbon bridge and at least two sulfur atoms. In some embodiments, the spacer connects to the mAB by a sulfide bond. In some embodiments, the spacer connects to the mAB through a thioether.
• A comprises at least one modified L-Alanine residue. In some embodiments, A comprises at least two modified L- Alanine residues. In some embodiments, L 1 comprises at least one sulfur. In some embodiments, L 1 comprises at least two sulfurs. In some embodiments, A comprises at least one modified L-Alanine residue that is connected to at least one sulfur of L 1 . In some embodiments, at least one modified L-Alanine residue is from an L-Cysteine residue of a peptide before conjugation. In some embodiments, at least one sulfur of L 1 is from an L-Cysteine of a peptide before conjugation. In some embodiments, A and L 1 together comprise at least one thioether.
• Linker may be a peptide
• Linker may include an oligosaccharide.
• Linker may include chitosan.
• L 2 may include Linker and -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• L 2 may include Linker and -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• Linker may include -(CH 2 ) endeavour- where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• Linker may include -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• Linker may include Val-Cit-PAB, Val-Ala- PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly- Arg, Ala- Ala- Asn-P AB , Ala-PAB, PAB, or the like.
• Linker may include any combination of peptide, oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala- Ala-Asn-PAB, Ala-PAB, PAB, and the like.
• the spacer may include a peptide.
• the spacer may include an oligosaccharide.
• the spacer may include chitosan.
• the spacer may include -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• L 1 may include a component including a 4-carbon bridge and -(CH 2 ) devis- where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• the spacer may include -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• L 1 may include a component including a 4-carbon bridge and -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
• the spacer may include Val-Cit-PAB, Val-Ala- PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly- Arg, Ala- Ala- Asn-P AB , Ala-PAB, PAB, or the like.
• the spacer may be any combination of peptide, oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)- PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn- PAB, Ala-PAB, PAB, and the like.
• L 1 may include a 4-carbon bridge. In some embodiments, L 1 may include a 4-carbon bridge through a fused aromatic ring. In some embodiments, L 1 may include a spacer and component including a 4-carbon bridge throu h a fused aromatic ring. In some embodiments, L 1 may include, but is not limited
• the agent-conjugate having the structure of Formula I has the structure of Formula la:
• S-linked portion of A comprises a modified L-Alanine residue
• the structure indicated by may include a fragment selected from the roup consisting of:
• the S-linked (sulfur-linked) portion of A comprises a modified L-Alanine residue. In some embodiments, the S-linked (sulfur- linked) portion of A comprises a modified L-Alanine residue that is connected to the sulfur of L 1 . In some embodiments, the S-linked (sulfur-linked) portion of A comprises a modified L-Alanine residue wherein the modified L-Alanine component of A is from an L-Cysteine residue of a peptide before conjugation. In some embodiments, the sulfur of L 1 is from an L-Cysteine of a peptide before conjugation. In some embodiments, A and L 1 comprise a thioether. In some embodiments, the compound having the structure of Formula la may be formed from a peptide that includes at least one L-Cysteine where the
• L-Cysteine provides a modified L-Alanine of A and a sulfur of .
• the compound having the structure of Formula la may be formed from a peptide that includes at least two L-Cysteine where the two L-Cysteine provide
• the a ogent-conjugate having the structure of Formula I has the structure of Formula lb:
• the A-component may be a targeting moiety
• the E-component may be a heteroaryl or heterocyclyl
• L 3 may be an optionally substituted Ci-C 6 alkyl, or L 3 may be null, when L 3 is null the sulfur is directly connected to the E-component
• L 4 may be an optionally substituted Ci-C 6 alkyl, or L 4 may be null, when L 4 is null the sulfur is directly connected to the E-component.
• L 3 may be -(CH 2 )-; and L 4 may be -(CH 2 )-.
• L 3 may be null; and L 4 may be null.
• the E-component includes a fragment selected from the group consisting of:
• the active agent may be selected from the group consisting of tubulin binders, DNA alkylators, DNA intercalator, enzyme inhibitors, immune modulators, peptides, and nucleotides.
• At least one L 2 includes -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, at least one L 2 includes -(CH 2 CH 2 0)n- where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, at least one L 2 includes Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe- Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala- Asn-PAB, Ala-PAB, or PAB.
• At least one L 2 includes a peptide, an oligosaccharide, -(CH 2 ) consult-, - (CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe- Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala- Asn-PAB, Ala-PAB, or PAB.
• at least one L 2 may comprise, consist of, or consist essentially of:
• the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugate having the structure of Formula I has the structure of [0142] In some embodiments, the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugate having the structure of F rmula I has the structure of
• the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugate having the structure of Formula I has the structure of
• the agent-conjugates may include one or more components selected from the group consisting of an amino acid, an amino acid residue, an amino acid analog, and a modified amino acid.
• targeting moiety refers to a structure that binds or associates with a biological moiety or fragment thereof.
• the targeting moiety may be an antibody. In some embodiments, the targeting moiety may be a monoclonal antibody (mAB). In some embodiments, the targeting moiety may be an antibody fragment, surrogate, or variant. In some embodiments, the targeting moiety may be a protein ligand. In some embodiments, the targeting moiety may be a protein scaffold. In some embodiments, the targeting moiety may be a peptide. In some embodiments, the targeting moiety may be RNA or DNA. In some embodiments, the targeting moiety may be a RNA or DNA fragment. In some embodiments, the targeting moiety may be a small molecule ligand.
• mAB monoclonal antibody
• the targeting moiety may be an antibody fragment, surrogate, or variant.
• the targeting moiety may be a protein ligand. In some embodiments, the targeting moiety may be a protein scaffold. In some embodiments, the targeting moiety may be a peptide. In some embodiments, the targeting moiety may be RNA or DNA. In some
• the targeting moiety may be an antibody fragment described in Janthur et al., "Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice," Int. J. Mol. Sci. 2012, 13, 16020-16045, the disclosure of which is incorporated herein by reference in its entirety.
• the targeting moiety may be an antibody fragment described in Trail, PA, "Antibody Drug Conjugates as Cancer Therapeutics," Antibodies 2013, 2, 113-129, the disclosure of which is incorporated herein by reference in its entirety.
• the targeting moiety may be HuM195-Ac-225, HuM195-Bi-213, Anyara (naptumomab estafenatox; ABR-217620), AS1409, Zevalin (ibritumomab tiuxetan), BIIB015, BT-062, Neuradiab, CDX-1307, CR011-vcMMAE, Trastuzumab-DMl (R3502), Bexxar (tositumomab), IMGN242, IMGN388, IMGN901, 131 I-labetuzumab, IMMU-102 ( 90 Y-epratuzumab), IMMU-107 ( 90 Y-clivatuzumab tetraxetan), MDX-1203, CAT-8015, EMD 273063 (hul4.18-IL2), Tucotuzumab celmoleukin (EMD 273066; h
• the targeting moiety may comprise, consist of, or consist essentially of the antibody portion of HuM195-Ac-225, HuM195-Bi-213, Anyara (naptumomab estafenatox; ABR-217620), AS 1409, Zevalin (ibritumomab tiuxetan), BIIB015, BT-062, Neuradiab, CDX-1307, CR011-vcMMAE, Trastuzumab- DMl (R3502), Bexxar (tositumomab), IMGN242, IMGN388, IMGN901, 131 I- labetuzumab, IMMU-102 ( 90 Y-epratuzumab), IMMU-107 ( 90 Y-clivatuzumab tetraxetan), MDX-1203, CAT-8015, EMD 273063 (hul4.18-IL2), Tucotuzumab celmoleuk
• the targeting moiety may be Brentuximab vedotin, Trastuzumab emtansine, Inotuzumab ozogamicin, Lorvotuzumab mertansine, Glembatumumab vedotin, SAR3419, Moxetumomab pasudotox, Moxetumomab pasudotox, AGS-16M8F, AGS-16M8F, BIIB-015, BT-062, IMGN-388, or IMGN-388.
• the targeting moiety may comprise, consist of, or consist essentially of the antibody portion of Brentuximab vedotin, Trastuzumab emtansine, Inotuzumab ozogamicin, Lorvotuzumab mertansine, Glembatumumab vedotin, SAR3419, Moxetumomab pasudotox, Moxetumomab pasudotox, AGS-16M8F, AGS-16M8F, BIIB-015, BT-062, IMGN-388, or IMGN-388.
• the targeting moiety may comprise, consist of, or consist essentially of Brentuximab, Inotuzumab, Gemtuzumab, Milatuzumab, Trastuzumab, Glembatumomab, Lorvotuzumab, or Labestuzumab.
• peptide refers to a structure including one or more components each individually selected from the group consisting of an amino acid, an amino acid residue, an amino acid analog, and a modified amino acid. The components are typically joined to each other through an amide bond.
• the peptide such as the antibody, is PEGylated.
• PEGylation can provide, for example, increased stability and/or efficacy of the polypeptide.
• Methods for PEGylation known in the art can be used in the methods and compositions provided herein.
• Such methods include, but are not limited to, those provided in "Comparative Binding of Disulfide-Bridged PEG-Fabs” Khalili et al., Bioconjugate Chemistry (2012), 23(11), 2262-2277; "Site-Specific PEGylation at Histidine Tags” Cong et al, Bioconjugate Chemistry (2012), 23(2), 248-263; "Disulfide bridge based PEGylation of proteins” Brocchini et al., Advanced Drug Delivery Reviews (2008), 60(1), 3-12; “Site-Specific PEGylation of Protein Disulfide Bonds Using a Three- Carbon Bridge” Balan et al, Bioconjugate Chemistry (2007), 18(1), 61-76; "Site-specific PEGylation of native disulfide bonds in therapeutic proteins” Shaunak et al., Nature Chemical Biology (2006), 2(6), 312-313; "PEG derivative conjugated proteins and peptides for use in pharmaceuticals” Godwin et al, WO
• amino acid includes naturally occurring amino acids, a molecule having a nitrogen available for forming an amide bond and a carboxylic acid, a molecule of the general formula NH 2 -CHR-COOH or the residue within a peptide bearing the parent amino acid, where "R” is one of a number of different side chains.
• R can be a substituent found in naturally occurring amino acids.
• R can also be a substituent referring to one that is not of the naturally occurring amino acids.
• amino acid residue refers to the portion of the amino acid which remains after losing a water molecule when it is joined to another amino acid.
• amino acid analog refers to a structural derivative of an amino acid parent compound that often differs from it by a single element.
• modified amino acid refers to an amino acid bearing an "R” substituent that does not correspond to one of the twenty genetically coded amino acids.
• the abbreviations for the genetically encoded L- enantiomeric amino acids are conventional and are as follows:
• amino acid residues in the active agent-conjugate can be replaced with other amino acid residues without significantly deleteriously affecting, and in many cases even enhancing, the activity of the peptides.
• altered or mutated forms of the active agent-conjugate wherein at least one defined amino acid residue in the structure is substituted with another amino acid residue or derivative and/or analog thereof. It will be recognized that in preferred embodiments, the amino acid substitutions are conservative, i.e., the replacing amino acid residue has physical and chemical properties that are similar to the amino acid residue being replaced.
• the amino acids can be conveniently classified into two main categories—hydrophilic and hydrophobic—depending primarily on the physical-chemical characteristics of the amino acid side chain. These two main categories can be further classified into subcategories that more distinctly define the characteristics of the amino acid side chains.
• hydrophilic amino acids can be further subdivided into acidic, basic and polar amino acids.
• hydrophobic amino acids can be further subdivided into nonpolar and aromatic amino acids.
• the definitions of the various categories of amino acids are as follows:
• hydrophilic amino acid refers to an amino acid exhibiting a hydrophobicity of less than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al, 1984, J. Mol. Biol. 179: 125-142. Genetically encoded hydrophilic amino acids include Thr (T), Ser (S), His (H), Glu (E), Asn (N), Gin (Q), Asp (D), Lys (K) and Arg (R).
• hydrophobic amino acid refers to an amino acid exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg, 1984, J. Mol. Biol. 179:1.25-142. Genetically encoded hydrophobic amino acids include Pro (P), He (I), Phe (F), Val (V), Leu (L), Trp (W), Met (M), Ala (A), Gly (G) and Tyr (Y).
• acidic amino acid refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Glu (E) and Asp (D).
• basic amino acid refers to a hydrophilic amino acid having a side chain pK value of greater than 7.
• Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion.
• Genetically encoded basic amino acids include His (H), Arg (R) and Lys (K).
• polar amino acid refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
• Genetically encoded polar amino acids include Asn (N), Gin (Q) Ser (S) and Thr (T).
• nonpolar amino acid refers to a hydrophobic amino acid having a side chain that is uncharged at physiological pH and which has bonds in which the pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar).
• Genetically encoded nonpolar amino acids include Leu (L), Val (V), lie (I), Met (M), Gly (G) and Ala (A).
• aromatic amino acid refers to a hydrophobic amino acid with a side chain having at least one aromatic or heteroaromatic ring.
• the aromatic or heteroaromatic ring may contain one or more substituents such as—OH,— SH,— CN,— F,—CI,—Br,—I,— N0 2 ,—NO,— NH 2 ,— NHR,— NRR,— C(0)R,— C(0)OH,— C(0)OR,— C(0)NH 2 ,— C(0)NHR,— C(0)NRR and the like where each R is independently (Ci - C 6 ) alkyl, substituted (Ci - C 6 ) alkyl, (Ci - C 6 ) alkenyl, substituted (Ci - C 6 ) alkenyl, (Ci - C 6 ) alkynyl, substituted (Ci - C 6 ) alkynyl, (C 5 - C 2 o) aryl
• aliphatic amino acid refers to a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include Ala (A), Val (V), Leu (L) and lie (I).
• Cys (C) is unusual in that it can form disulfide bridges with other Cys (C) residues or other sulfanyl-containing amino acids.
• the ability of Cys (C) residues (and other amino acids with— SH containing side chains) to exist in a peptide in either the reduced free — SH or oxidized disulfide-bridged form affects whether Cys (C) residues contribute net hydrophobic or hydrophilic character to a peptide.
• Cys (C) exhibits a hydrophobicity of 0.29 according to the normalized consensus scale of Eisenberg (Eisenberg, 1984, supra), it is to be understood that for purposes of the preferred embodiments Cys (C) is categorized as a polar hydrophilic amino acid, notwithstanding the general classifications defined above.
• amino acids having side chains exhibiting two or more physical-chemical properties can be included in multiple categories.
• amino acid side chains having aromatic moieties that are further substituted with polar substituents, such as Tyr (Y) may exhibit both aromatic hydrophobic properties and polar or hydrophilic properties, and can therefore be included in both the aromatic and polar categories.
• polar substituents such as Tyr (Y)
• the amino acid substitutions need not be, and in certain embodiments preferably are not, restricted to the genetically encoded amino acids.
• the active agent-conjugate may contain genetically non-encoded amino acids.
• amino acid residues in the active agent-conjugate may be substituted with naturally occurring non-encoded amino acids and synthetic amino acids.
• Certain commonly encountered amino acids which provide useful substitutions for the active agent-conjugates include, but are not limited to, ⁇ -alanine ( ⁇ - Ala) and other omega-amino acids such as 3-aminopropionic acid, 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and so forth; a-aminoisobutyric acid (Aib); ⁇ - aminohexanoic acid (Aha); ⁇ -aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGly); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine (t-BuG); N-methylisoleucine (Melle); phenylglycine (Phg); cyclohexylalanine (Cha); norleucine (Nle); naphthylalanine (Nal); 4-phenylgly
• Aromatic F Y, W Phg, Nal, Thi, Tic, Phe (4-Cl), Phe (2-F),
• the amino acids of the active agent-conjugate will be substituted with L-enantiomeric amino acids, the substitutions are not limited to L-enantiomeric amino acids.
• the peptides may advantageously be composed of at least one D-enantiomeric amino acid. Peptides containing such D-amino acids are thought to be more stable to degradation in the oral cavity, gut or serum than are peptides composed exclusively of L-amino acids.
• Examples include, but are not limited to, the following:
• the reaction was conducted at 0-40 °C for 0.5-40 hours with gentle stirring or shaking, monitored by HIC-HPLC.
• the resultant crude ADC product underwent necessary down-stream steps of desalt, buffet changes/formulation, and optionally, purification, using the state -of-art procedures.
• the final ADC product was characterized by HIC-HPLC, SEC, RP-HPLC, and optionally LC- MS.
• the average DAR was calculated by UV absorption and/or MS spectroscopy.
• Method 1-1 Linker and Drug connected via a carbamate bond using General procedure G or I for activation and carbamate formation and General procedure C, D, or F for removal of protective groups.
• Method 1-3 Active molecule containing a carboxylic acid moiety connected to an alkoxyamino linker via formation of hydoxamate (General procedure A or B), followed by removal of protective groups.
• Step 3 Introducing the final functional groups prior to conjugation
• amino acid sulfonamide derivatives 11 were synthesized according to previously reported procedure (AR IVOC 2004 (xii) 14-22, or
• Compound 13 was synthesized using the general procedures described above as following: DIC/HOAt mediated amide bond formation (General procedure B) between Boc-N-Me-Val-Val-Dil-Dap-OH (compound 1) and amine 11, followed by removal of Boc (General procedure C). The final compound was purified by reverse phase HPLC to give compound 13 as a white powder after lyophilization. MS m/z Calcd for C42H70N6O9S 834.5, Found 835.6 ([M+H] + ).
• Compound 32 was synthesized using the general procedures described above as following: DIC/HOAt mediated amide bond formation (General procedure B) between Auristatin F and compound 26, followed by removal of Fmoc (General procedure D), reaction with acid 30 (General procedure A), and reduction of the nitro group to amino group.
• the reaction was conducted at 0-40 °C for 0.5-40 hours with gentle stirring or shaking, monitored by HIC-HPLC.
• the resultant crude ADC product underwent necessary down-stream steps of desalt, buffet changes/formulation, and optionally, purification, using the state -of-art procedures.
• the final ADC product was characterized by HIC-HPLC, SEC, RP-HPLC, and optionally LC-MS.
• the average DAR was calculated by UV absorption and/or MS spectroscopy.
• Trastuzumab and compound 34 were combined in various drug/antibody ratios under as described in the General Conjugation Procedure. Trastuzumab was incubated with 10 mM TCEP stock solution at 37°C for 0.5 to 40 hours. After reduction, the excess of TCEP was removed by a gel filtration column. The reduced trastuzumab was then mixed with compound 34 in drug/antibody ratio range from 1 to 10 at 0 to 40°C. After overnight reaction, excess compound 34 was removed from Trastuzumab-c-34 conjugate by a gel filtration column. Purified Trastuzumab-c-34 conjugates stored at 4 to -20°C and to be used for in vitro and in vivo tests.
• Figure 1 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 5.5: 1, where DAR represents the number of drugs conjugated per antibody.
• Figure 2 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 6: 1, where DAR represents the number of drugs conjugated per antibody.
• Figure 3 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 1 :6.5, where DAR represents the number of drugs conjugated per antibody.
• Figure 4 shows the HIC-HPLC chromatogram product of reacting drug and antibody at a drug/antibody ratio of 1 :4, where DAR represents the number of drugs conjugated per antibody.
• Figure 4 further shows HIC-HPLC chromatograms for individually isolated fractions of DAR 1, DAR 2, DAR 3, DAR 4 and DAR 5 peaks purified using FPLC.
• Figure 5 shows HIC- HPLC chromatograms for each FPLC fraction, and, inset, an overlay of the peaks to demonstrate relative purity of each peak.
• the antibody drug conjugates were the analyzed for cytotoxicity.
• the cell lines used were SK-BR-3 human breast adenocarcinoma (HER2 triple positive), HCC1954 human Ductal Carcinoma (HER2 triple positive). These cells were available from ATCC.
• SK-BR-3 cells were grown in McCoy's 5A medium (Caisson Labs, North Logan, UT) supplemented with 10% fetal bovine serum.
• HCC1954 cells were grown in RPMI-1640 medium (Caisson Labs, North Logan, UT) supplemented with 10% fetal bovine serum.
• SK-BR-3 cells were plated in 96-well plates at approximately 7,500 cells/well, and HCC1954 cells were plated in 96-well plates at approximately 20,000 cells/well.
• Antibody-drug conjugates were added in duplicates in the same day. After 72 hour incubation at 37°C, CellTiter-Glo (Promega, Madison, WI) were added and cell viability was determined as describe by the manufacture's protocol. The percent viability was determined as following:
• % Viability Average Luminescence Value of the duplicates (treated wells) / Average Luminescence Value of the untreated wells
• Figure 7 shows viability of SK-BR-3 cells for seven samples, ADC Cl (DAR1 from Figures 4 and 5), ADC C2 (DAR2 from Figures 4 and 5), ADC C3 (DAR3 from Figures 4 and 5), ADC C4 (DAR4 from Figures 4 and 5), ADC 5 (DAR5 from Figures 4 and 5), SeaGen (ADC prepared following published Seattle Genetics method), and T-DMl (ADC prepared following published Immunogen method).
• ADC Cl DAR1 from Figures 4 and 5
• ADC C2 DAR2 from Figures 4 and 5
• ADC C3 DAR3 from Figures 4 and 5
• ADC C4 DAR4 from Figures 4 and 5
• ADC 5 DAR5 from Figures 4 and 5
• SeaGen ADC prepared following published Seattle Genetics method
• T-DMl ADC prepared following published Immunogen method
• Figure 8 shows viability of HCC1954 cells for seven samples, ADC Cl (DAR1 from Figures 4 and 5), ADC C2 (DAR2 from Figures 4 and 5), ADC C3 (DAR3 from Figures 4 and 5), ADC C4 (DAR4 from Figures 4 and 5), ADC C5 (DAR5 from Figures 4 and 5), ADC VC-M MAE was prepared following published Seattle Genetics method), and T-DMl (ADC prepared following published Immunogen method).
• Figure 10 shows viability of SK-BR-3 cells for four samples, both ADC C6 (DAR2.4) and ADC C7 (DAR3.1) were prepared using the General Conjugation Procedure and purified by a gel filtration column. SeaGen (ADC prepared following published Seattle Genetics method), and T-DMl (ADC prepared following published Immunogen method).
• Figure 11 shows viability of HCC1954 cells for four samples, ADC C6 (DAR2.4 from Figure 10), ADC C7 (DAR3.1 from Figure 10), ADC VC-M MAE was prepared following published Seattle Genetics method), and T-DM1 (ADC prepared following published Immunogen method).
• Trastuzumab and compound 42 were combined in various drug/antibody ratios under conditions where Trastuzumab was incubated with 10 mM TCEP stock solution at 37 °C for 0.5 to 40 hours. After reduction, the excess of TCEP was removed by a gel filtration column. The reduced Trastuzumab was then mixed with compound 42 in drug/antibody ratio range from 1 to 10 at 0 to 40 °C. After overnight reaction, excess compound 42 was removed from Trastuzumab-c-34 conjugate by a gel filtration column. Purified Trastuzumab-c-42 conjugates stored at 4 to -20 °C and to be used for in vitro and in vivo tests.
• Trastuzumab and compound 40 were combined in various drug/antibody ratios under conditions where Trastuzumab was incubated with 10 mM TCEP stock solution at 37°C for 0.5 to 40 hours. After reduction, the excess of TCEP was removed by a gel filtration column. The reduced Trastuzumab was then mixed with compound 40 in drug/antibody ratio range from 1 to 10 at 0 to 40 °C. After overnight reaction, excess compound 40 was removed from Trastuzumab-c-34 conjugate by a gel filtration column. Purified Trastuzumab-c-40 conjugates stored at 4 to -20 °C and to be used for in vitro and in vivo tests.
• the Trastuzumab -compound 42 and Trastuzumab -compound 42 conjugates were the analyzed for cytotoxicity.
• the cytotoxicity methods were performed as described above.
• Figure 12 shows viability of SK-BR-3 cells for four samples, Trastuzumab-c-Duo3 (Trastuzumab-compound 42 conjugate), Trastuzumab-c-Duo6 (Trastuzumab-compound 40 conjugate), Trastuzumab-vc-MMAE (prepared following published Seattle Genetics method), and Trastuzumab-c-MMAE (Trastuzumab- compound 34 conjugate, prepared following published Seattle Genetics method).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Immunology (AREA)
• Epidemiology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Molecular Biology (AREA)
• Biochemistry (AREA)
• Genetics & Genomics (AREA)
• Biophysics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Cell Biology (AREA)
• Diabetes (AREA)
• Oncology (AREA)
• Gastroenterology & Hepatology (AREA)
• Obesity (AREA)
• Hematology (AREA)
• Emergency Medicine (AREA)
• Endocrinology (AREA)
• Communicable Diseases (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Priority Applications (11)

Applications Claiming Priority (8)

Related Child Applications (2)

Publications (1)

Family

ID=49584226

Family Applications (3)

Family Applications After (2)

Country Status (7)

Cited By (57)

Families Citing this family (85)

Citations (8)

Family Cites Families (46)

• 2013
  • 2013-05-14 WO PCT/US2013/041026 patent/WO2013173391A1/en not_active Ceased
  • 2013-05-14 EP EP13790623.6A patent/EP2849790B1/en active Active
  • 2013-05-14 US US14/401,115 patent/US9981046B2/en active Active
  • 2013-05-14 US US14/401,114 patent/US9884127B2/en active Active
  • 2013-05-14 JP JP2015512770A patent/JP6239598B2/ja active Active
  • 2013-05-14 WO PCT/US2013/041027 patent/WO2013173392A1/en not_active Ceased
  • 2013-05-14 EP EP19167808.5A patent/EP3590541B1/en active Active
  • 2013-05-14 WO PCT/US2013/041028 patent/WO2013173393A1/en not_active Ceased
  • 2013-05-14 ES ES13790623T patent/ES2734259T3/es active Active
  • 2013-05-14 EP EP21189993.5A patent/EP3925627A1/en active Pending
  • 2013-05-14 EP EP13790777.0A patent/EP2850059A4/en not_active Ceased
  • 2013-05-14 CN CN201710584374.6A patent/CN107982545B/zh active Active
  • 2013-05-14 ES ES19167808T patent/ES2887208T3/es active Active
  • 2013-05-14 JP JP2015512771A patent/JP6280103B2/ja not_active Expired - Fee Related
  • 2013-05-14 CN CN201380025775.8A patent/CN104662000B/zh active Active
  • 2013-05-14 CN CN201380025785.1A patent/CN104640572B/zh active Active
  • 2013-05-14 JP JP2015512769A patent/JP6239597B2/ja active Active
  • 2013-05-14 HK HK15108783.7A patent/HK1208216A1/xx unknown
  • 2013-05-14 EP EP18199921.0A patent/EP3520817A1/en active Pending
  • 2013-05-14 EP EP13790334.0A patent/EP2849797B1/en active Active
  • 2013-05-14 CN CN201380025774.3A patent/CN104379168B/zh active Active
  • 2013-05-14 US US14/401,318 patent/US9801951B2/en not_active Expired - Fee Related
• 2017
  • 2017-08-17 US US15/679,599 patent/US20180085471A1/en not_active Abandoned
  • 2017-11-01 JP JP2017212053A patent/JP2018058851A/ja active Pending
  • 2017-11-01 JP JP2017212167A patent/JP2018052951A/ja active Pending
  • 2017-12-26 US US15/854,742 patent/US10967071B2/en active Active
• 2021
  • 2021-03-01 US US17/189,135 patent/US12115228B2/en active Active
• 2024
  • 2024-09-04 US US18/824,613 patent/US20250135024A1/en active Pending

Patent Citations (8)

Non-Patent Citations (11)

Also Published As

Similar Documents

Legal Events